(Q24241268)

26 October 2023

5

Brian R Davidson

Brian R

Davidson

1 reference

19160303

26 October 2023

Andrew Kenneth Burroughs

4

Andrew K Burroughs

Andrew K

Burroughs

1 reference

26 October 2023

3

Elias Xirouchakis

Elias

Xirouchakis

1 reference

26 October 2023

2

Bujar Osmani

Bujar

Osmani

1 reference

19160303

Cochrane Database of Systematic Reviews

26 October 2023

language of work or name

1 reference

21 January 2009

0 references

published in

0 references

cites work

Bias in meta-analysis detected by a simple, graphical test

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006803.PUB2

Reported methodologic quality and discrepancies between large and small randomized trials in meta-analyses

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006803.PUB2

Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006803.PUB2

7 January 2021

Antiviral prophylactic intervention for hepatitis C virus in patients undergoing liver transplantation

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006803.PUB2

7 January 2021

Peginterferon alfa-2a for hepatitis C after liver transplantation: two randomized, controlled trials

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006803.PUB2

7 January 2021

A randomized study comparing ribavirin and interferon alfa monotherapy for hepatitis C recurrence after liver transplantation

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006803.PUB2

7 January 2021

Ischemic preconditioning in deceased donor liver transplantation: a prospective randomized clinical trial of safety and efficacy

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006803.PUB2

7 January 2021

Effect of ischemic preconditioning in whole liver transplantation from deceased donors. A pilot study

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006803.PUB2

7 January 2021

Sustained virologic response to therapy of recurrent hepatitis C after liver transplantation is related to early virologic response and dose adherence

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006803.PUB2

7 January 2021

Quantifying heterogeneity in a meta-analysis

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006803.PUB2

7 January 2021

What to add to nothing? Use and avoidance of continuity corrections in meta-analysis of sparse data

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006803.PUB2

7 January 2021

Methods for combining randomized clinical trials: strengths and limitations.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006803.PUB2

7 January 2021

A comparison of methods to detect publication bias in meta-analysis.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006803.PUB2

7 January 2021

The influence of viral genotypes and rejection episodes on the recurrence of hepatitis C after liver transplantation

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006803.PUB2

7 January 2021

Meta-analysis in clinical trials

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006803.PUB2

7 January 2021

Sustained virological response to antiviral therapy reduces mortality in HCV reinfection after liver transplantation

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006803.PUB2

7 January 2021

A randomized study on Peg-interferon alfa-2a with or without ribavirin in liver transplant recipients with recurrent hepatitis C.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006803.PUB2

7 January 2021

Ribavirin in the treatment of recurrent hepatitis C after liver transplantation: difficult to manage but essential for success.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006803.PUB2

7 January 2021

Combination therapy with peginterferon alpha-2B and ribavirin in liver transplant recipients with recurrent HCV infection: preliminary results of an open prospective study

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006803.PUB2

7 January 2021

Interferon Alfa-2A and ribavirin therapy for hepatitis C recurrence after liver transplantation.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006803.PUB2

7 January 2021

Recurrence of hepatitis C after liver transplantation: follow-up and treatment

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006803.PUB2

7 January 2021

Combination therapy of interferon alpha-2B and ribavirin for recurrent hepatitis C after liver transplantation

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006803.PUB2

7 January 2021

Recurrence of HCV infection in liver transplant patients

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006803.PUB2

7 January 2021

Recurrence of hepatitis C in liver transplants from elderly donors aged more than 75 years

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006803.PUB2

7 January 2021

Daily interferon Alpha-2B and ribavirin combination therapy for liver transplant patients with chronic hepatitis C infection

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006803.PUB2

7 January 2021

Hepatitis C recurrence in liver transplant recipients

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006803.PUB2

7 January 2021

The CONSORT statement: revised recommendations for improving the quality of reports of parallel-group randomised trials

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006803.PUB2

7 January 2021

Does quality of reports of randomised trials affect estimates of intervention efficacy reported in meta-analyses?

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006803.PUB2

7 January 2021

Literature searching for randomized controlled trials used in Cochrane reviews: rapid versus exhaustive searches

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006803.PUB2

7 January 2021

The association between hepatitis C infection and survival after orthotopic liver transplantation

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006803.PUB2

7 January 2021

Interferon-alpha 2b plus ribavirin in patients with chronic hepatitis C after liver transplantation: a randomized study.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006803.PUB2

7 January 2021

Chronic hepatitis C after liver transplantation: a randomized study

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006803.PUB2

7 January 2021

Epoetin alfa maintains ribavirin dose in HCV-infected patients: a prospective, double-blind, randomized controlled study

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006803.PUB2

7 January 2021

Efficacy of antiviral therapy on hepatitis C recurrence after liver transplantation: a randomized controlled study.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006803.PUB2

7 January 2021

A model to predict severe HCV-related disease following liver transplantation.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006803.PUB2

7 January 2021

Steroid-free liver transplantation using rabbit antithymocyte globulin induction: results of a prospective randomized trial

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006803.PUB2

7 January 2021

A pilot study of the tolerability and efficacy of antiviral therapy in hepatitis C virus-infected patients awaiting liver transplantation

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006803.PUB2

7 January 2021

Intention-to-treat analysis: implications for quantitative and qualitative research

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006803.PUB2

7 January 2021

Orthotopic liver transplantation for hepatitis C: outcome, effect of immunosuppression, and causes of retransplantation during an 8-year single-center experience

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006803.PUB2

7 January 2021

Daily interferon therapy for hepatitis C virus infection in liver transplant recipients

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006803.PUB2

7 January 2021

Liver transplantation and hepatitis C virus: systematic review of antiviral therapy.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006803.PUB2

7 January 2021

Review article: the treatment of hepatitis C virus recurrence after liver transplantation

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006803.PUB2

7 January 2021

Extended right split liver graft for primary transplantation in children and adults

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006803.PUB2

7 January 2021

10.1002/14651858.CD006803.PUB2

Identifiers

DOI

0 references

Fatcat ID

release_sbkljhj65jgchppbfkngukdhae

0 references